FXS5626 for Non-Infectious Eye Inflammation
Part of Eyes & vision clinical trials.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 and able to understand and follow study procedures
- BMI between 18–30 kg/m² (weight at least 50 kg for men, 45 kg for women)
- Diagnosis of non-infectious uveitis (inflammation in the middle, back, or all layers of the eye) that is actively present despite steroid treatment
- Currently taking oral prednisone (10–60 mg per day) or equivalent steroid for at least 2 weeks
- Willing to use effective contraception and not plan pregnancy or donate sperm/eggs for 1 month after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This trial tests a new drug called tulisokibart for people with active inflammation in the back of the eye (uveitis). The drug may help reduce inflammation and prevent vision loss.
This study tests a combination of two medicines, mycophenolate mofetil and adalimumab, to help control eye inflammation (uveitis) and reduce the need for steroids. It is for people who still have active inflammation despite taking a steroid medication like prednisone.
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
This study tests a new cell therapy (TRX103) to see if it can safely reduce inflammation in people with active uveitis that is not caused by infection. The treatment aims to calm the immune system to control the disease and may help avoid long-term steroid use.
This study follows people with non-infectious uveitis (inflammation inside the eye) that affects the middle or back of the eye. It aims to understand the disease better and see how different treatments work, which may help improve future care.
Hear when a new Active Non-anterior, Non-infectious Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.